	US 12,350,323 B2
	Cellular adjuvants for viral infection
Kayvan Niazi, Culver City, CA (US); Raymond Wong, Los Angeles, CA (US); Peter Sieling, Culver City, CA (US); and Philip T. Liu, Culver City, CA (US)
Assigned to NantBio, Inc., Culver City, CA (US)
Filed by NantBio, Inc., Culver City, CA (US)
Filed on May 14, 2024, as Appl. No. 18/664,198.
Application 18/664,198 is a continuation of application No. 17/684,121, filed on Mar. 1, 2022, granted, now 12,220,452.
Application 17/684,121 is a continuation of application No. 16/536,962, filed on Aug. 9, 2019, granted, now 11,298,414.
Claims priority of provisional application 62/717,560, filed on Aug. 10, 2018.
Prior Publication US 2024/0342262 A1, Oct. 17, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); A61K 39/00 (2006.01); A61K 39/108 (2006.01); C12N 15/861 (2006.01); A61K 9/00 (2006.01)

CPC A61K 39/0258 (2013.01) [A61K 39/0002 (2013.01); C12N 15/861 (2013.01); A61K 9/0019 (2013.01); A61K 2039/605 (2013.01); C12N 2770/16034 (2013.01)]

18 Claims

1. A vaccine composition, comprising:

an adjuvant component and a therapeutic component;

wherein the therapeutic component comprises an adenovirus having a genome that includes a recombinant sequence encoding an antigen, wherein the sequence is operably linked to a promoter to drive expression of the antigen in a cell of the patient;

wherein the adjuvant component comprises a BCG (Bacille Calmette Guerin) non-host cell; and

wherein the BCG non-host cell is provided at an MOI (multiplicity of infection) of less than 5.